These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 35158141)

  • 1. Potential of RP-UHPLC-DAD-MS for the qualitative and quantitative analysis of sofosbuvir in film coated tablets and profiling degradants.
    Contreras MDM; Morales-Soto A; Segura-Carretero A; Valverde J
    J Pharm Anal; 2017 Aug; 7(4):208-213. PubMed ID: 29404040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher sensitive selective spectrofluorometric determination of ritonavir in the presence of nirmatrelvir: application to new FDA approved co-packaged COVID-19 pharmaceutical dosage and spiked human plasma.
    Imam MS; Abdelazim AH; Ramzy S; Almrasy AA; Gamal M; Batubara AS
    BMC Chem; 2023 Sep; 17(1):120. PubMed ID: 37735663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Green adherent spectrophotometric determination of molnupiravir based on computational calculations; application to a recently FDA-approved pharmaceutical dosage form.
    Abdelazim AH; Abourehab MAS; Abd Elhalim LM; Almrasy AA; Ramzy S
    Spectrochim Acta A Mol Biomol Spectrosc; 2023 Jan; 285():121911. PubMed ID: 36174404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.
    Asselah T; Marcellin P
    Liver Int; 2014 Feb; 34 Suppl 1():60-8. PubMed ID: 24373080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HCV F1/F2 patients: treat now or continue to wait.
    Shiffman ML; Benhamou Y
    Liver Int; 2014 Feb; 34 Suppl 1():79-84. PubMed ID: 24373082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of different spectrophotometric methods for quantitative analysis of direct acting antiviral drugs simeprevir and sofosbuvir.
    Ramzy S; Abdelazim AH
    Spectrochim Acta A Mol Biomol Spectrosc; 2022 May; 272():121012. PubMed ID: 35158141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Treatment and Predictors of Response to Sofosbuvir Plus Simeprevir in Hepatitis C Virus with Genotype-4 Infection.
    Ahmed OA; Elsebaey MA; Fouad MHA; Elkadeem M; Badawi R; Khayyal A; Soliman S; Negm MS; Abd-Elsalam S
    Infect Disord Drug Targets; 2020; 20(3):389-395. PubMed ID: 30569878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simeprevir and sofosbuvir for treatment of hepatitis C infection.
    Chopp S; Vanderwall R; Hult A; Klepser M
    Am J Health Syst Pharm; 2015 Sep; 72(17):1445-55. PubMed ID: 26294237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients.
    Eletreby R; Elakel W; Said M; El Kassas M; Seif S; Elbaz T; El Raziky M; Abdel Rehim S; Zaky S; Fouad R; Gamal Eldeen H; Abdo M; Korany M; Yosry A; El Serafy M; El-Sayed MH; ElShazly Y; Waked I; Doss W; Esmat G
    Liver Int; 2017 Apr; 37(4):534-541. PubMed ID: 27712017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C.
    Izzo I; Zanotti P; Chirico C; Casari S; Villanacci V; Salemme M; Biasi L; Festa E; Castelli F
    Infection; 2016 Dec; 44(6):811-812. PubMed ID: 27311809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort.
    Laurain A; Metivier S; Haour G; Larrey D; Dorival C; Hezode C; Zoulim F; Marcellin P; Bourliere M; Zarski JP; Thabut D; Alric L; Ganne-Carrie N; Cales P; Bronowicki JP; Riachi G; Geist C; Causse X; Abergel A; Chazouilleres O; Mathurin P; Guyader D; Samuel D; Tran A; Loustaud-Ratti V; Petrov-Sanchez V; Diallo A; Luzivika-Nzinga C; Fontaine H; Carrat F; Pol S;
    BMC Infect Dis; 2019 Apr; 19(1):300. PubMed ID: 30940090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stress stability study of simeprevir, a hepatitis C virus inhibitor, using feasible TLC-spectro-densitometry: application to pharmaceutical dosage form and human plasma.
    Mohammed BS; Hamad AE; Derayea SM
    RSC Adv; 2020 Jun; 10(36):21100-21107. PubMed ID: 35518774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2
    Gammeltoft KA; Zhou Y; Duarte Hernandez CR; Galli A; Offersgaard A; Costa R; Pham LV; Fahnøe U; Feng S; Scheel TKH; Ramirez S; Bukh J; Gottwein JM
    Antimicrob Agents Chemother; 2021 Aug; 65(9):e0268020. PubMed ID: 34097489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir.
    Lo HS; Hui KPY; Lai HM; He X; Khan KS; Kaur S; Huang J; Li Z; Chan AKN; Cheung HH; Ng KC; Ho JCW; Chen YW; Ma B; Cheung PM; Shin D; Wang K; Lee MH; Selisko B; Eydoux C; Guillemot JC; Canard B; Wu KP; Liang PH; Dikic I; Zuo Z; Chan FKL; Hui DSC; Mok VCT; Wong KB; Mok CKP; Ko H; Aik WS; Chan MCW; Ng WL
    ACS Cent Sci; 2021 May; 7(5):792-802. PubMed ID: 34075346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug combination therapy for emerging viral diseases.
    Shyr ZA; Cheng YS; Lo DC; Zheng W
    Drug Discov Today; 2021 Oct; 26(10):2367-2376. PubMed ID: 34023496
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.